20 articles
New research shows combining weight-loss medications with hormone therapy could transform health outcomes for obese men with low testosterone.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
University of Pennsylvania researchers investigated how insulin resistance and testosterone interact in women after menopause.
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
Comprehensive review reveals estrogen-only therapy carries lower breast cancer risk than combined hormone treatments during menopause.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
NIH study identifies metabolic mechanism behind controversial skin condition and demonstrates successful treatment with mitochondrial complex I inhibitors.
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
A Bayesian network meta-analysis of 19 RCTs finds retatrutide tops weight loss but dual agonists offer the best efficacy-safety balance.
Low-intensity resistance training with blood flow restriction improved muscle strength and mitochondrial function better than conventional exercise.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Clinical trial tested whether metformin could enhance resistance training benefits for muscle mass and strength in older adults.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
20-week study reveals how sequencing HIIT and resistance training affects metabolic health in women with morbid obesity.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Study finds both interpersonal therapy and health education help military teens improve weight and metabolic health outcomes.
Three months of romosozumab plus denosumab matched 12 months of romosozumab alone for bone strength gains in postmenopausal women.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
